Continue Reading
Full article on Unknown
Femasys Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement
Market Intelligence Analysis
AI-Powered
Why This Matters
Femasys Inc. has been granted a 180-day extension by Nasdaq to regain compliance with the minimum bid price requirement, giving the company more time to address its stock price issue.
Market Impact
Market impact analysis based on neutral sentiment with 75% confidence.
Sentiment
Neutral
AI Confidence
75%
Time Horizon
Short Term
Article Context
Note: This is a brief excerpt for context. Click below to read the full article on the original source.
ATLANTA, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY) (“Femasys” or the “Company”), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, today announced that on January 13, 2026, it received notification from The Nasdaq Stock Market LLC ("Nasdaq") that Nasdaq approved the Company's request for an additional 180-calendar day extension to regain compliance with the minimum closing bid price
Original article published by
Unknown
on January 14, 2026.
Analysis and insights provided by AnalystMarkets AI.
Analysis and insights provided by AnalystMarkets AI.